Sponsored Post: AstraZeneca PLC could cite new data from across the innovative lung cancer portfolio at the IASLC 2020 World Conference on Lung Cancer. Meanwhile, check the disclaimer on the landing pages. These other companies could be unprecedented as they are engaged in e-commerce websites in terms of return. Let's get started and converge here: https://prem.li/MustSeePromisingMobilePaymentsMarket
According To Allied Market Research Mobile Payments Are On Track To Exceed $12 Trillion. Learn More
According To Allied Market Research Mobile Payments Are On Track To Exceed $12 Trillion. Learn More
AZN's trials have more credible results than Moderna, because they did actual tests rather than subjective call backs from participants. Lower dose, lower cost to store and ship, high production capacity, and less than 1/4 the cost of Moderna.
s
Astra Zeneca today asked officially for approval in EU. Should rise MASSIVLY.
F
“The Oxford-AstraZeneca vaccine requires only normal refrigeration for both short- and longer-term storage and distribution. AstraZeneca has promised to make as many as three billion doses available in 2021—more than any other Covid-19 vaccine maker—and at a cheaper price.” - Wall Street Journal
Bullish
J
Selling today most of my shares for profits, if it goes down I will buy them again. This stock has been going up and down and I plan to play the game. I hope no losing a big jump of the stock.
Bullish
i
AZN stock behaves like a stock based on fundamentals. Unlike, many of it's peers that trade based on manipulation. Not a gambling stock but a good stable, long-term investment!
J
Deutsche bank initiates coverage of $AZN with 'Buy'
J
Holding my shares for this year. Honestly, I thought AZN would be higher by now, but I think it is undervalued when the overall market is overpriced. I feel my money is safe here and with a lot of potential.
Bullish
M
Now approved for these 5 countries. 1. UK, 350M 2. India 3. Mexico 4. Argentina 5. Thailand
India's drug regulator is set to approve on Friday a coronavirus vaccine developed by AstraZeneca and Oxford University for emergency use, three sources with knowledge of the matter said.
The decision would pave the way for the vaccine's rollout in the world's second-most populous country which, after the United States, has the highest number of COVID-19 infections in the world.
Britain and Argentina have already authorised the vaccine for urgent public use.
C
1/2 dose trial not a slip up? Exploits FDAs bureacracy to delay need to seek US approval thereby allowing limited supply to be sold more profitably elsewhere due to 21% decline of the $
M
Seems like no one is caring the approval of Covid vaccines anymore. This is proved with PFE, MRNA and AZN. Not sure whether the trend continues downside or will reverse towards upside from here. I am thinking if JNJ results are positive and also if people start focusing on INO with some good reviews for sure all these might still slide further. I exited my small position with AZN with a $1 profit and will watch before I rethink in investing again. I am not a long term investor and also I never shorted stocks. I wish all the best for all who is holding this stock for a long term which for sure will give minimum 20% return.
s
India has followed the U.K. and granted emergency approval for the coronavirus vaccine developed by AstraZeneca Plc and the University of Oxford, the first step in its plan to inoculate citizens in the country that’s home to the world’s second-largest Covid-19 outbreak.
In a brief statement on Sunday, the Drugs Controller General of India V.G. Somani, confirmed the approval of the AstraZeneca shot being produced locally by the Serum Institute of India Ltd. -- the world’s largest vaccine maker by volume.
D
Go up .share price could reach 65$ to 80$..hope so . Best wishes
G
To fellow Posters: I admit I was wrong about AZN going to 131 / share on Jan 15th. From Gary RN
Bullish
C
Market needs to wake up to the fact that AZN is up in Europe
I
While the developing world including India, bet everything on the vaccine against coronavirus developed by Oxford and Astrazeneca, Australian scientists have cast a doubt on the efficacy of the vaccine, raising concerns that it is not effective enough to tame the pandemic through herd immunity. They urged the government to review its inoculation strategy. The scientists feel the vaccine made by BioNTech-Pfizer and Moderna has shown higher efficacy in trials and the government must procure more doses from them. However, the Australian government said it will not go back on the Oxford-AstraZeneca vaccine
J
Can anyone explain how the divident works on how and when it is paid out . From reading online it seems to be due at the end of Q1 and is .90c per share.
B
I love the recurring vaccination revenue every year thereafter, Lots of orders world wide
AstraZeneca PLC could cite new data from across the innovative lung cancer portfolio at the IASLC 2020 World Conference on Lung Cancer. Meanwhile, check the disclaimer on the landing pages. These other companies could be unprecedented as they are engaged in e-commerce websites in terms of return. Let's get started and converge here: https://prem.li/MustSeePromisingMobilePaymentsMarket
Lower dose, lower cost to store and ship, high production capacity,
and less than 1/4 the cost of Moderna.
Should rise MASSIVLY.
- Wall Street Journal
1. UK, 350M
2. India
3. Mexico
4. Argentina
5. Thailand
https://www.channelnewsasia.com/news/asia/covid-19-thailand-orders-35-million-doses-astrazeneca-vaccine-13897378
The decision would pave the way for the vaccine's rollout in the world's second-most populous country which, after the United States, has the highest number of COVID-19 infections in the world.
Britain and Argentina have already authorised the vaccine for urgent public use.
In a brief statement on Sunday, the Drugs Controller General of India V.G. Somani, confirmed the approval of the AstraZeneca shot being produced locally by the Serum Institute of India Ltd. -- the world’s largest vaccine maker by volume.
I admit I was wrong about AZN going to 131 / share on Jan 15th.
From Gary RN